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Abstract Methadone, a regimen for the treatment of opioid
dependency, was found to induce the expression of CCR5, a co-
receptor for human immunodeficiency virus (HIV)/simian form
of HIV (SIV) entry, on human CEM x174 lymphocytes. Both
CCR5 mRNA and protein were elevated in methadone-treated
cells. A concomitant increase of mu opioid receptors was also
observed. Upon methadone exposure, SIVmac239-infected
CEM x174 cells released greater amounts of virus particles as
revealed by both the number of syncytia formation and reverse
transcriptase activities. Similar methadone effect was not
observed on CEM x174 cells infected with other simian
retroviruses that do not depend on CCR5 for cellular entry.
These studies raise concerns considering methadone as an
innocuous morphine substitute. 1 2002 Published by Elsevier
Science B.V. on behalf of the Federation of European Biochem-
ical Societies.
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1. Introduction
Drug addiction is a major risk factor for human immuno-
de¢ciency virus (HIV) infection worldwide [1,2]. Injection
drug use accounts for as many as 50% of new cases of HIV
infection in the USA yearly [3]. Methadone is a synthetic
opiate receptor agonist that is rapidly absorbed and slowly
eliminated from the plasma [4]. Unlike most other modalities
where research was not involved, methadone was developed as
a maintenance drug for opioid addicts through the initial
assiduous research e¡orts of Dole and Nyswander [5]. Today,
for opiate abuse, methadone treatment represents a widely
o¡ered and widely accepted modality [6,7]. Approximately
179 000 patients were in treatment in 1998 [7]. Methadone
programs have been reported to e¡ectively block withdrawal
symptoms and reduce a patient’s craving for cocaine [8] and
heroin [9]. It was also reported that the likelihood of hetero-
sexual HIV-1 transmission from a seropositive methadone-
maintained drug user to his/her seronegative, non-drug user/
steady sex partner is low [10]. It has been suggested that
heroin addicts undergoing methadone treatment have a better
functioning immune system [11,12]. E¡ective drug abuse treat-
ment such as methadone maintenance has hence been sug-
gested a cost-e¡ective intervention for slowing the spread of
AIDS among drug users [1,2,13].
In a previous study, we found that morphine will activate
mu opioid receptors of human lymphocytic cells [14] and up-
regulate cell surface CCR5 expression [15], rendering the cells
more susceptible to simian form of HIV (SIV)mac239 infec-
tion [15]. Opioid receptor and chemokine receptor CCR5 are
both G protein-coupled receptors containing seven transmem-
brane domains that respond in consensus toward extracellular
stimuli [14,15]. SIVmac239, a simian counterpart of HIV, has
been used in the infection of rhesus monkeys leading to
AIDS-like disease [16]. Using monkey monocytes and neutro-
phils to study the e¡ect of opioids on immune functions, we
have demonstrated that both morphine and methadone inhib-
it chemokine-mediated chemotaxis of the cells [17]. In a study
evaluating LAAM (L-K-acetyl-methadol), a derivative of
methadone, we reported that T helper cell functions of rhesus
monkeys were signi¢cantly impaired if the monkeys received
LAAM intramuscularly for the treatment of morphine depen-
dency [18]. It thus appears that methadone may have mor-
phine-like immunomodulatory activities on immune cells. This
paper will address the e¡ect of methadone on lymphocytes,
with particular interest on its e¡ect on the expression of cell
surface mu opioid and CCR5 receptors and the subsequent
release of viral particles from SIVmac239-infected cells.
2. Materials and methods
2.1. Cell culture
CEM x174 cell line, a human lymphocytic cell line which is highly
susceptible to SIVmac239 infection and routinely utilized by various
investigators for the propagation of SIVmac239 [15], was used in this
study. CEM x174 was maintained in RPMI 1640 medium supple-
mented with 10% heat-inactivated bovine calf serum, 2 mM L-gluta-
mine, 25 mM HEPES, 100 U/ml penicillin and 100 Wg/ml streptomy-
cin. Cells were grown at 37‡C in a CO2 incubator.
2.2. Methadone or morphine treatment
CEM x174 cells in culture were diluted 1:3 with fresh medium every
3^4 days. At the time of dilution, methadone hydrochloride (Mal-
linckrodt), morphine sulfate (Mallinckrodt) or H2O (as control) was
added. When naloxone was included in the experiment involving
methadone, cells were ¢rst incubated with naloxone for 15 min at
37‡C before the addition of methadone. The initial cell density was
2U105 cells/ml and incubation continued at 37‡C for the indicated
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time. Cells were collected by centrifugation and washed twice with
1UPBS before use.
2.3. Competitive reverse transcriptase-polymerase chain reactions
(RT-PCR)
Opioid-treated or control CEM x174 cells were lysed in Trizol re-
agent (Gibco BRL) and total RNA was isolated by phenol^chloro-
form extraction and isopropyl alcohol precipitation. Quantitative
analyses of gene expression of chemokine receptor CCR5 and mu
opioid receptors were performed in competitive RT-PCR. The meth-
ods for the construction of competitive molecules containing segments
of CCR5 or mu with internal deletions, the speci¢c RT-PCR condi-
tions, the gel analysis, and the ¢nal calculation of the amount of
cDNA synthesized using CA-Cricket Graph III (Computer Associ-
ates) have been described in detail in previous publications [14,15].
2.4. Western blot analysis
Total protein was isolated from opioid-treated or control CEM
x174 cells with lysis bu¡er (20 mM Tris^HCl, pH 7.4; 0.1% sodium
dodecyl sulfate (SDS), 1% Triton X-100 and 1% sodium deoxycho-
late). The method of Western blotting was previously described
[14,15,19]. Brie£y, samples of 20 Wg protein were analyzed by 10%
SDS^polyacrylamide gel electrophoresis (PAGE) with prestained
SDS^PAGE protein standards (Bio-Rad) running in parallel to reveal
the molecular mass of the test proteins. Polypeptide bands resolved in
SDS^PAGE gels were electroblotted onto Immobilon-PVDF (Milli-
pore) ¢lters. After blocking, the ¢lters were incubated with primary
antibodies against target proteins followed by incubation with horse-
radish peroxidase-conjugated secondary antibodies. Immunocom-
plexes resolved by electrophoresis were visualized by incubation of
the ¢lters with the SuperSignal substrate (Pierce) followed by exposure
to a Fuji autoradiography ¢lm (Fisher). Results were quanti¢ed by
densitometry and experiments were repeated at least six times. The
primary antibodies used in this study were rabbit anti-CCR5-NT
(ANASPEC Incorp., San Jose, CA, USA) and rabbit anti-mu opioid
receptor (MOR)-1 (INCSTAR Corp., Stillwater, MN, USA) for the
detection of CCR5 and mu, respectively. The horseradish peroxidase-
conjugated secondary antibodies used to detect the primary antibodies
were purchased from Promega (Madison, WI, USA).
2.5. Infection of CEM x174 with SIVmac239 or simian type D
retrovirus (SRV)
Infection of CEM x174 cells with SIVmac239 or SRV and quanti-
tation of viral infectivity by micro-RT assay were performed as de-
scribed previously [15,20]. SIVmac239 (3U103 TCID50/ml) was resus-
pended at a 1:50 dilution. 50 Wl of the diluted virus was added to 104
CEM x174 cells in a 96-well, £at-bottomed plate, and incubated over-
night at 37‡C in a 5% CO2 incubator. On the following day, meth-
adone was added to the corresponding wells at 4.0 and 20 WM ¢nal
concentrations. On days 6 and 8, supernatant fractions were collected
and viral infectivity was determined by the micro-RT assay. The pres-
ence of syncytia formation was also evaluated with an inverted micro-
scope. Titers for SRV serotype 2 were determined by the Raji cell
infectivity assay and the Raji cell line was obtained from American
Type Culture Collection.
2.6. Statistics
Results are presented as the meanTS.E.M. Statistical signi¢cance
was evaluated by Student’s t-test.
3. Results
3.1. E¡ect of methadone treatment on expression of mu opioid
receptors in CEM x174
As previously described, by use of primer sequences corre-
sponding to bases 921^950 and 1332^1361 of the human brain
MOR sequence (Mestek et al., accession number L29301) in
RT-PCR ampli¢cation of CEM x174 RNA, it was found that
CEM x174 cells synthesized a 441 bp segment that was 100%
homologous to the corresponding segment in human brain
MOR [14]. To determine the densities of CEM x174 MOR,
plasmids containing CEM x174 MOR with a 62 bp deletion
were constructed and used in quantitative RT-PCR analysis
[14]. In order to investigate the e¡ect of methadone treatment
on the gene expression of CEM x174 MOR, the amount of
cDNA ampli¢ed by competitive RT-PCR from cells treated
with methadone was compared with that of untreated or mor-
phine-treated cells. Samples were taken 12, 24, 36 and 48 h
post-treatment for analysis. The results showed that like mor-
phine [14], methadone treatment of CEM x174 cells increased
MOR expression (Fig. 1A). By 24 h post-treatment, 10 WM
methadone increased MOR expression by 180% and 10 nM
methadone increased MOR by 330%.
Subsequent experiments showed that the methadone-in-
duced increase in CEM x174 MOR gene expression correlated
Fig. 1. E¡ect of methadone on CEM x174 MOR. A: RT-PCR anal-
ysis. The amount of MOR transcripts (expressed as cDNA) synthe-
sized in CEM x174 cells was determined by the competitive RT-
PCR procedure after treatment of the cells with 10 nM or 10 WM
methadone hydrochloride for the indicated time. Experiments with
H2O-treated (as control) and morphine-treated cells were performed
in parallel for comparison purposes. B: Western blot analysis. Total
protein (20 Wg/lane) from 10 nM or 10 WM methadone- or mor-
phine-treated CEM x174 cells was subjected to SDS^PAGE, blotted
onto ¢lters, probed with the antibody against neuronal MOR and
detected by horseradish peroxidase-conjugated secondary antibody
as described in Section 2. Data analyzed by densitometry are pre-
sented. The amount of MOR cDNA (A) or MOR protein (B) syn-
thesized from H2O-treated (control) cells was designated as 100%.
MTD, methadone; MS, morphine. Bar, standard error (A, n=4; B,
n=6). *P6 0.05, **P6 0.01.
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with the amount of MOR protein synthesized in the cells as
determined by Western blot analysis. The increase of MOR
protein was greatest at 36 h as opposed to 24 h post-treatment
(Fig. 1B), indicating that mRNA (Fig. 1A) has a faster turn-
over rate than protein synthesis. After 36 h treatment with 10
WM or 10 nM methadone, CEM x174 MOR protein was in-
creased by 230 and 200%, respectively (Fig. 1B). The metha-
done-induced mu opioid receptor expression was blocked by
pretreatment of the cells with naloxone, a mu opioid receptor
antagonist (Fig. 2). Preliminary studies showed that like the
e¡ect of morphine [19], activation of mu opioid receptor by
methadone induced a series of intracellular reactions including
the stimulation of ERK2 and the 85 kDa mitogen-activated
protein kinase (data not shown).
3.2. E¡ect of methadone treatment on expression of chemokine
receptor CCR5 in CEM x174
To determine the e¡ect of methadone treatment on the ex-
pression of chemokine receptor CCR5 at the transcriptional
level, a competitive RT-PCR analysis of CEM x174 CCR5
was performed. Using primer sequences corresponding to
bases 44^63 and 1139^1157 of the published human CCR5
sequence, CEM x174 cells synthesized a 1114 bp segment
[15]. To determine CCR5 receptor densities on CEM x174
cells, plasmids containing CCR5 segments with 96 bp dele-
tions were constructed and used in quantitative RT-PCR as
previously described [15]. With this method, the e¡ect of
methadone on the gene expression of CCR5 was studied
and the amount of CCR5 cDNA in methadone-treated cells
was compared with that in morphine-treated or control (H2O-
treated) cells. Samples were taken 12, 24, 36 and 48 h post-
treatment for analysis. The results showed that as with mor-
phine treatment [15], methadone increased CCR5 gene expres-
sion. In comparison with the control cells, 10 WM methadone
increased CCR5 expression by 120, 200 and 230% upon 12, 24
and 36 h exposure, respectively (Fig. 3A). Further studies
revealed that the methadone-induced increase in CCR5 gene
expression could be identi¢ed at the protein level by both
Western blot analysis (Fig. 3B) and £ow cytometry studies
(data not shown), although the protein increase was evident
at 36 and 48 h post-infection (Fig. 3B), again later than the
increase of mRNA expression (Fig. 3A). Dose^response ex-
periments indicated that methadone exerted its optimal e¡ect
on inducing CCR5 protein of CEM x174 cells at both 10 WM
and 10 nM concentrations (Fig. 4).
3.3. E¡ect of methadone on viral replication of
SIVmac239-infected CEM x174
With the apparent increase in CCR5, a co-receptor for
Fig. 2. E¡ect of naloxone treatment on methadone-induced MOR
protein expression. Experiments were performed as in Fig. 1B.
When naloxone was included in the treatment, naloxone was added
to the cells 15 min before the addition of methadone (see Section
2). Control, H2O-treated cells. Cells were harvested 36 h post-treat-
ment for analysis and the concentrations of methadone (MTD) or
naloxone (NAL) used for treatment were 10 WM each. Bar, stan-
dard error (n=3). *P6 0.05 (compared with the control). 3P6 0.05
(compared with MTD).
Fig. 3. E¡ect of methadone on CEM x174 CCR5. A: RT-PCR
analysis. The amount of CCR5 transcripts (expressed as cDNA)
synthesized in CEM x174 cells was determined by the competitive
RT-PCR procedure after treatment of the cells with 10 nM or
10 WM methadone hydrochloride for the indicated time. Experi-
ments with H2O-treated (as control) and morphine-treated cells
were performed in parallel for comparison purposes. B: Western
blot analysis. Total protein (20 Wg/lane) from 10 nM or 10 WM
methadone- or morphine-treated CEM x174 cells was subjected to
SDS^PAGE, blotted onto ¢lters, probed with the antibody against
CCR5 and detected by horseradish peroxidase-conjugated secondary
antibody as described in Section 2. Data analyzed by densitometry
are presented. The amount of CCR5 cDNA (A) or CCR5 protein
(B) synthesized from H2O-treated (control) cells was designated as
100%. MTD, methadone; MS, morphine. Bar, standard error (A,
n=2; B, n=6). *P6 0.05.
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SIVmac entry, CEM x174 cells would be expected to be more
susceptible to SIVmac239 infection. CEM x174 cells were in-
fected with SIVmac239 in the presence of methadone and
both syncytia formation and viral RT activity were moni-
tored. The results (Fig. 5A, Tables 1A and 1B) show that
methadone increased both the number of syncytia and the
RT activity of CEM x174 cells. Cells treated with 4 WM meth-
adone for 8 days showed the greatest amount of syncytia and
RT activities (Fig. 5A, Tables 1A and 1B). On the other hand,
similar infection of CEM x174 cells with SRV, viruses that do
not depend on CCR5 for cellular entry, showed no signi¢cant
di¡erence in virus-induced syncytia formation whether the
infection took place in the presence or absence of methadone
(Fig. 5B).
4. Discussion
The above studies indicate that the e¡ects exerted by meth-
adone on human lymphocytes are likely similar to the e¡ects
caused by morphine. Like morphine, methadone activates mu
opioid receptors in a naloxone-reversible manner (Figs. 1, 2).
The activation of mu opioid receptors up-regulates CCR5 re-
ceptors (Figs. 3, 4). The precise mechanism by which metha-
done induces CCR5 expression remains to be determined. As
postulated [15], methadone may act like morphine and induce
CCR5 by activating the release of cytokines (e.g. TNF-K or
IL-2) known to stimulate chemokine receptor expression or,
Fig. 4. E¡ect of methadone on CCR5 protein expression ^ a dose^
response curve. Experiments were performed as in Fig. 3B except
that a series of concentrations of methadone was used in the treat-
ment of CEM x174 cells and the treatment was for 36 h. Bar, stan-
dard error (n=5). *P6 0.05, **P6 0.01.
Fig. 5. E¡ect of methadone on SIVmac239 or SRV infection of
CEM x174 cells. CEM x174 cells were infected with SIVmac239 (A)
or SRV serotype 2 (B) in the presence of methadone at concentra-
tions of 0, 4 or 20 WM. Syncytia formation was shown as giant pro-
toplasmic mass that resulted from fusion of cytopathic cells. The
data were reproducible in three independent experiments.
Table 1A
Mean number of syncytia formation for SIVmac239a
Day Methadone concentration
0 WM 4 .0 WM 20.0 WM
6 0b 0 1.2
7 0 0.8 2
8 1.2 7.3 3.2
aData were reproducible in three independent experiments.
Table 1B
E¡ect of methadone on RT activity of SIV- or SRV-infected CEM x174 cellsa
Virus Methadone concentration
0 WM 4.0 WM 20.0 WM
Day 6 Day 8 Day 6 Day 8 Day 6 Day 8
SIVmac239b 804 (1.0)c 881 (1.0) 836 (1.1) 1231 (1.4) 1030 (1.3) 1078 (1.3)
SRV-2d 620 (1.0) 780 (1.0) 612 (1.0) 789 (1.0) 631 (1.0) 795 (1.0)
aData were reproducible in three independent experiments.
bThe P value is 9 0.05 by analysis of variance (ANOVA), considered signi¢cant. One-way ANOVA was performed using GraphPad InStat ver-
sion 3.00 for Mac, GraphPad Software, San Diego, CA, USA, www.graphpad.com.
cCPM ratio between sample and no-methadone control.
dThe P value is s 0.1 by ANOVA, considered not signi¢cant.
The RT activity was assayed using standard [32P]dTTP incorporation [20]. The mean cpm for the scintillation £uid was 120.
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alternatively, methadone may inhibit the synthesis of certain
chemokines (e.g. RANTES, MIP-1K or MIP-1L) which cause
internalization of CCR5. In as much as CCR5 is a co-receptor
facilitating cellular entry of AIDS virus, increasing CCR5
receptors renders the cells more susceptible to SIVmac239
infection. Indeed, methadone treatment of CEM x174 caused
the cells to release a greater amount of SIVmac239 virus, but
similar treatment had no e¡ect on the virus production of
SRV-2, the simian retroviruses that do not use CCR5 for
cell entry (Fig. 5, Tables 1A and 1B).
Heroin is a synthetic morphine derivative and a common
form of opiate sought by street users. Heroin is injected intra-
venously because it is poorly absorbed by the oral route. Once
in the body, heroin is rapidly (within 10^15 min) converted to
6-acetylmorphine and then to morphine, which has a plasma
half life of 2 h [21]. Methadone, a long-acting opioid with a
plasma half life of 15^40 h [21], is readily absorbed if admin-
istered orally and has been used as the drug of choice for the
treatment of heroin addiction [1,2,5]. Little is known about
the e¡ect of methadone on the immune functions of treated
patients. An earlier study determining the activities of natural
killer cells and lymphocyte subsets in methadone maintenance
patients in comparison with parenteral heroin abusers sug-
gested that signi¢cant abnormalities of cellular immunity in
parenteral heroin abusers can be ‘normalized’ by successful
long-term methadone treatment [22]. Accordingly, methadone
maintenance therapy for treatment of opiate abuse has given
sanguine hope for slowing the spread of AIDS. A low HIV
seroconversion rate was reported among injection drug users
enrolled in methadone programs of Los Angeles [23] and New
York [24], although HIV patients in New York did not expe-
rience greater survival [25]. On the other hand, other studies
indicated that in Amsterdam, prescription of methadone to
illicit drug users is not su⁄cient to halt the spread of HIV
[26]. Likewise, in Thailand, HIV-1 transmission risk remains
high among Bangkok drug users despite methadone treatment
[27].
The results of the present study which compared the e¡ects
of methadone and morphine on cellular receptors of human
lymphocytic cells and the subsequent virus production after
infection, together with other reports which showed the im-
munotoxic properties of methadone [28,29], suggest that
methadone itself may not countervail the detrimental e¡ects
of morphine/heroin on the immune system. Rather, the de-
cline of HIV infection among drug users enrolled in the meth-
adone maintenance programs may be largely attributed to
treatment paraphernalia such as reduction in needle use/shar-
ing and other high risk behaviors as well as educational in-
terventions. Furthermore, it was found that consistent partic-
ipation in a methadone maintenance program facilitated
therapy with an antiretroviral regimen [30]. Therefore, it ap-
pears that further biological and immunological studies of
methadone as well as a more detailed epidemiological surveil-
lance of methadone-treated HIV patients are necessary to es-
tablish methadone as the drug of choice for the treatment of
opioid addiction.
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